DBIA
RXII

Dumont & Blake Investment Advisors’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Dumont & Blake Investment Advisors’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-39,000
Closed -$14K – 193
2016
Q3 		$14K Hold
39,000
– – 0.01% 177
2016
Q2 		$18K Hold
39,000
– – 0.01% 176
2016
Q1 		$53K Buy
39,000
+8,000
+26% +$10.9K 0.03% 158
2015
Q4 		$46K Buy
31,000
+325
+1% +$482 0.02% 162
2015
Q3 		$48K Buy
30,675
+1,000
+3% +$1.56K 0.03% 153
2015
Q2 		$50K Hold
29,675
– – 0.02% 154
2015
Q1 		$41K Hold
29,675
– – 0.02% 154
2014
Q4 		$45K Hold
29,675
– – 0.02% 149
2014
Q3 		$61K Hold
29,675
– – 0.03% 143
2014
Q2 		$91K Hold
29,675
– – 0.05% 145
2014
Q1 		$74K Buy
29,675
+2,000
+7% +$4.99K 0.04% 141
2013
Q4 		$137K Buy
27,675
+2,575
+10% +$12.7K 0.07% 137
2013
Q3 		$57K Buy
25,100
+6,500
+35% +$14.8K 0.03% 136
2013
Q2 		$41K Buy
+18,600
New +$41K 0.02% 114

Dumont & Blake Investment Advisors's RXII Position: Q4 2016 in Review

Dumont & Blake Investment Advisors sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 39,000 shares — an estimated $14K sold.

Dumont & Blake Investment Advisors first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $137K in Q4 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.

  • Dumont & Blake Investment Advisors reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
  • Dumont & Blake Investment Advisors sold 39,000 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $14K.
  • Dumont & Blake Investment Advisors first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
  • Dumont & Blake Investment Advisors's GALENA BIOPHARMA INC COM position peaked at $137K in Q4 2013.
  • 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.

Based on Dumont & Blake Investment Advisors's 13F filing for Q4 2016, filed 11 Jan 2017.